XTL Biopharmaceuticals Ltd. announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. XTL previously announced that it has submitted a Pre-IND meeting package to the US Food and Drug Administration and expects to receive written responses regarding its proposed clinical study in the coming weeks. A Phase 2b clinical trial of hCDR1 was previously completed and the compound has shown a favorable safety profile in over 400 patients and efficacy in at least one clinically relevant endpoint. Submission of this clinical trial protocol marks a milestone for XTL in its development of hCDR1, which the Company is developing under license from Yeda, the technology transfer arm of the world-renowned Weizmann Institute of Science.